Skip to main content

Table 1 Sociodemographic and clinical characteristics of 251 women included, according to menopausal status

From: How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

  

Menopausal status

 

All women

Pre-menopausal

Peri-menopasual

Post-menopausal

p

251 (100%)

44 (17.5%)

70 (27.9%)

137 (54.6%)

 

Sociodemographic variables

     

Age (years; median –[IQR])

52 (48–55)

46 (45–48)

49 (47–52)

55 (52–57)

< 0.001

Country of origin

     

 Spain

187 (74.5%)

26 (59.1%)

53 (75.7%)

108 (78.8%)

0.032

 Others

64 (25.5%)

18 (40.9%)

17 (24.3%)

29 (21.2%)

 

Educational level

     

 None or primary

21 (8.4%)

2 (4.5%)

7 (10.0%)

12 (8.8%)

0.574

 Secondary or university

230 (91.6%)

42 (95.5%)

63 (90.0%)

125 (91.2%)

 

Current occupational status

     

 Employed

137 (54.6%)

24 (54.5%)

41 (58.6%)

72 (52.6%)

0.525

 Unemployed

45 (17.9%)

11 (25.0%)

11 (15.7%)

23 (16.8%)

 

 Other*

69 (27.5%)

9 (20.5%)

18 (25.7%)

42 (30.7%)

 

Current partner and cohabitation status

     

 Without partner

106 (42.2%)

16 (36.4%)

19 (27.1%)

71 (51.8%)

0.004

 With partner and living together

108 (43.0%)

24 (54.5%)

35 (50.0%)

49 (35.8%)

 

 With partner and not living together

37 (14.7%)

4 (9.1%)

16 (22.9%)

17 (12.4%)

 

Clinical variables

     

Body mass index (kg/m2)

     

 < 18.5

15 (6.0%)

3 (6.8%)

2 (2.9%)

10 (7.3%)

0.482

 18.5–24.9

136 (54.2%)

23 (52.3%)

39 (55.7%)

74 (54.0%)

 

 25–30

54 (21.5%)

10 (22.7%)

20 (28.6%)

24 (17.5%)

 

 > 30

39 (15.5%)

6 (13.6%)

7 (10.0%)

26 (19.0%)

 

 Unknown

7 (2.8%)

2 (4.5%)

2 (2.9%)

3 (2.2%)

 

Body mass index (kg/m2)

23.7 (21.2–28.0)

24.0 (22.0–26.7)

23.8 (21.2–27.7)

23.6 (21.0–28.7)

0.982

Hepatitis B

     

 Yes

60 (23.9%)

6 (13.6%)

18 (25.7%)

36 (26.3%)

0.335

 No

174 (69.3%)

33 (75.0%)

47 (67.1%)

94 (68.6%)

 

 Unknown

17 (6.8%)

5 (11.4%)

5 (7.1%)

7 (5.1%)

 

Hepatitis C

     

 Yes

60 (23.9%)

6 (13.6%)

16 (22.9%)

38 (27.7%)

0.204

 No

179 (71.3%)

34 (77.3%)

50 (71.4%)

95 (69.3%)

 

 Unknown

12 (4.8%)

4 (9.1%)

4 (5.7%)

4 (2.9%)

 

Diabetes mellitus

     

 Yes

18 (7.2%)

2 (4.5%)

4 (5.7%)

12 (8.8%)

0.549

 No

233 (92.8%)

42 (95.5%)

66 (94.3%)

125 (91.2%)

 

Osteoporosis

     

 Yes

37 (14.7%)

0 (0.0%)

7 (10.0%)

30 (21.9%)

< 0.001

 No

214 (85.3%)

44 (100.0%)

63 (90.0%)

107 (78.1%)

 

Smoking

     

 Current

115 (45.8%)

15 (34.1%)

35 (50.0%)

65 (47.4%)

0.215

 Never/past

136 (54.2%)

29 (65.9%)

35 (50.0%)

72 (52.6%)

 

Alcohol consumption

     

 Never/occasional (< 2 times/week)

202 (80.5%)

36 (81.8%)

56 (80.0%)

110 (80.3%)

0.969

 Frequent (≥ 2 times/week)

49 (19.5%)

8 (18.2%)

14 (20.0%)

27 (19.7%)

 

Drug use

     

 Never

154 (61.4%)

27 (61.4%)

43 (61.4%)

84 (61.3%)

0.522

 Sporadic use

8 (3.2%)

3 (6.8%)

3 (4.3%)

2 (1.5%)

 

 Regular past use

75 (29.9%)

13 (29.5%)

21 (30.0%)

41 (29.9%)

 

 Regular current use

14 (5.6%)

1 (2.3%)

3 (4.3%)

10 (7.3%)

 

Trouble failing asleep the last two weeks

     

 Never

137 (54.6%)

28 (63.6%)

44 (62.9%)

65 (47.4%)

0.165

 Less than twice a week

29 (11.6%)

5 (11.4%)

6 (8.6%)

18 (13.1%)

 

 More than 3 times a week

85 (33.9%)

11 (25.0%)

20 (28.6%)

54 (39.4%)

 

Social support (MOS-SSS-4item)

     

 Poor(score < 12)

43 (17.1%)

8 (18.2%)

4 (5.7%)

31 (22.6%)

0.009

 Normal(score ≥ 12)

208 (82.9%)

36 (81.8%)

66 (94.3%)

106 (77.4%)

 

Sexual intercourse during last year

     

 Yes

159 (63.3%)

33 (75.0%)

56 (80.0%)

70 (51.1%)

< 0.001

 No

92 (36.7%)

11 (25.0%)

14 (20.0%)

67 (48.9%)

 

Age at diagnosis (years; median[IQR])

42 (38–46)

39 (36.5–42)

40 (36–44)

45 (39–49)

< 0.001

HIV transmission mode

     

 Injecting drug user

30 (12.0%)

3 (6.8%)

10 (14.3%)

17 (12.4%)

0.293

 Heterosexual

210 (83.7%)

37 (84.1%)

59 (84.3%)

114 (83.2%)

 

 Others/Unknown

11 (4.4%)

4 (9.1%)

1 (1.4%)

6 (4.4%)

 

Time since HIV diagnoses (years)

     

 < 5

44 (18%)

10 (22.7%)

11 (15.7%)

23 (16.8%)

0.667

 5–10

85 (34%)

17 (38.6%)

24 (34.3%)

44 (32.1%)

 

 > 10

122 (49%)

17 (38.6%)

35 (50.0%)

70 (51.1%)

 

Antiretroviral treatment

     

 Yes

236 (94%)

42 (95.5%)

66 (94.3%)

128 (93.4%)

0.88

 No

15 (6%)

2 (4.5%)

4 (5.7%)

9 (6.6%)

 

Time with ART (years)

     

 Median (IQR)

7.5 (4.8–10.5)

6.8 (4.2–10.1)

7.8 (5.2–10.3)

7.5 (4.6–10.6)

0.471

ART adherence

     

 All pills

222 (94.1%)

39 (92.9%)

60 (90.9%)

123 (96.1%)

0.407

 Most of them

11 (4.7%)

3 (7.1%)

4 (6.1%)

4 (3.1%)

 

 Half of them or less

3 (1.3%)

0 (0.0%)

2 (3.0%)

1 (0.8%)

 

AIDS diagnosis

     

 Yes

52 (20.7%)

7 (15.9%)

14 (20.0%)

31 (22.6%)

0.623

 No

199 (79.3%)

37 (84.1%)

59 (84.3%)

106 (77.4%)

 

CD4 count at last visit (cells/µl)

     

 < 200

7 (2.8%)

0 (0.0%)

1 (1.4%)

6 (4.4%)

0.484

 200–500

60 (23.9%)

11 (25.0%)

15 (21.4%)

34 (24.8%)

 

 > 500

184 (73.3%)

33 (75.0%)

54 (77.1%)

97 (70.8%)

 

Median (IQR)

720 (491–960)

663 (500–925.5)

719.5 (527–959)

731 (476–1016)

0.929

Viral load at last visit

     

 Undetectable(≤ 200 copies/µl)

234 (93.2%)

41 (93.2%)

68 (97.1%)

125 (91.2%)

0.279

 Detectable(> 200 copies/µl)

17 (6.8%)

3 (6.8%)

2 (2.9%)

12 (8.8%)

 

Womens health variables

     

Age at menarche (years)

     

 < 13

98 (39%)

16 (36.4%)

28 (40.0%)

54 (39.4%)

0.990

 ≥ 13

149 (59%)

27 (61.4%)

41 (58.6%)

81 (59.1%)

 

 Unknown

4 (02%)

1 (2.3%)

1 (1.4%)

2 (1.5%)

 

Number of pregnancies

     

 None

36 (14.3%)

7 (15.9%)

13 (18.6%)

16 (11.7%)

0.344

 1 or 2

114 (45.4%)

17 (38.6%)

27 (38.6%)

70 (51.1%)

 

 ≥ 3

101 (40.2%)

20 (45.5%)

30 (42.9%)

51 (37.2%)

 
  1. Bold values are statistically significant
  2. IQR interquartile range, ART antiretroviral therapy, AIDS acquired immunodeficiency syndrome
  3. *Other: retired, housewife, students